EDAP TMS SA today announced the retention of Greenleaf Health LLC, a full service regulatory consulting firm. Greenleaf Health will provide the Company with high-level strategic guidance regarding the final stages of its Ablatherm-HIFU (High Intensity Focused Ultrasound) ENLIGHT U.S. Phase II/III clinical trial for the indication of low risk, localized prostate cancer.
I hope I am wrong, but based on my experience trading drug stocks (not medical device), stock price should not be this slow just 1-2 months before filing. Those "insiders" know more and act early. The continued #$%$ stock price really concerns me. I do not dream for $4 any time soon, seriously. Probably will out when it hits $3, if it ever does.
How could the data not be positive? This is not new technology, it's been proven tens of thousands of times in Europe, Britain, Canada and most of civilized world. I guess USA was either asleep at the switch, or FDA has been corrupted by big fat pharma.(or both)